Le Lézard
Classified in: Health, Science and technology
Subject: PLW

ADMINISTRATIVE LAW JUDGE ISSUES INITIAL DETERMINATION IN BIO-LAYER INTERFEROMETERS INVESTIGATION


PALO ALTO, Calif., July 6, 2023 /PRNewswire/ -- An Administrative Law Judge at the United States International Trade Commission (USITC) has announced the termination of the Section 337 investigation involving certain biolayer interferometers and components. In October 2022, Sartorius BioAnalytical Instruments, Inc. lodged a complaint with the USITC against Gator Bio, Inc., alleging the infringement of four US patents.

After conducting a thorough analysis, the presiding ALJ determined that the asserted claims of one of patents are invalid due to indefiniteness. Soon after, Sartorius voluntarily moved to terminate the remaining three patents from the investigation. On June 30, 2023, the ALJ issued an order terminating the investigation in its entirety.

Gator Bio holds a deep regard for intellectual property and firmly asserts that our next generation biolayer interferometry technology does not infringe on the intellectual property owned by other entities. We remain committed to continued innovation and the development of a robust product portfolio, while vigorously defending our intellectual property against any future challenges. Our goal is to create innovative products that enhance the productivity of biotherapeutics discovery and development.

About Gator Bio:

Gator Bio is a life sciences company providing bioanalytical systems to accelerate the development of therapeutics and diagnostics. The Gator next gen biolayer interferometry (BLI) instruments and biosensors enable real-time analysis of biomolecular interactions providing information on affinity, kinetics, concentration, and epitope binning, etc. Most importantly, Gator Bio's analytical capabilities enable better and faster characterization of drug candidates and viral vectors, thus providing greater value in drug development and gene therapy applications where existing methods have limitations in throughput, performance, and cost. The company is headquartered in Palo Alto, California with facilities in Shanghai and Suzhou, China. For more information, please visit www.gatorbio.com

Media and Investor Relations Contact:
Subodh Nimkar, Marketing Director
[email protected]
+1 650 575 0827
Website: http://www.gatorbio.com//
LinkedIn

SOURCE Gator Bio


These press releases may also interest you

at 17:41
Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, today announced the publication in JAMA Cardiology of two-year echocardiographic data from its REDUCE LAP-HF II randomized clinical trial of the Corvia® Atrial...

at 17:09
Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced a meeting of the Psychopharmacologic Drugs Advisory Committee on June 4 to discuss a new drug application for...

at 16:50
More than 12,600 people rallied together this weekend for BMO Walk so Kids Can Talk, in support of Kids Help Phone ? raising $3.7 million and counting for its #FeelOutLoud campaign....

at 16:50
Quest Diagnostics Incorporated , a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak on the company's strategy, performance and the latest market developments and trends during a fireside...

at 16:45
Danaher Corporation announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the at the Bank of America Securities Health Care Conference in Las Vegas, Nevada on Tuesday, May 14, 2024 at 10:40 a.m. PT. The event...

at 16:35
Precision BioSciences, Inc. , an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today...



News published on and distributed by: